Nippon Shinyaku, Elixirgen Sign EXG-7001 DMD Option Deal
KYOTO, Japan, June 26, 2026 Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen...
DMD
Advertisement
Capricor Reaches Key FDA Milestone in DMD
SAN DIEGO, June 26, 2026 Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has scheduled a...
CureDuchenne and Tevard Biosciences Advance DMD Therapy
NEWPORT BEACH, Calif., May 20, 2026 CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of...
Atossa Therapeutics Highlights (Z)-Endoxifen Potential in Duchenne Muscular Dystrophy Research
SEATTLE, May 20, 2026 Atossa Therapeutics announced that a new scientific manuscript exploring the utrophin-modulation potential of (Z)-endoxifen in...
GEMMABio Expands Gene Therapy Pipeline for Rare Diseases
PHILADELPHIA, May 14, 2026 GEMMA Biotherapeutics (GEMMABio) unveiled its new Duchenne muscular dystrophy (DMD) gene therapy program and presented...
Advertisement
